If you’ve already registered, please click here to log in to the webcast.

Human disease is a highly dynamic process. While next-generation genomic sequencing has provided enormous insight into the genetic underpinnings of human health and disease, dynamic measures that integrate changes in human pathobiology are still lacking in therapeutic development, as are measures of the influence of external factors including diet, lifestyle, microbes, and environmental exposures. The next advancements in drug discovery and development will require new data layers that complement genomics and capture these dynamic processes.

This webcast will explore how next-generation mass spectrometry can broadly measure a diverse range of small-molecule biomarkers, including uncharacterized compounds, to enable improved understanding of dynamic human processes and host-disease and host-environment interactions that influence biology, disease progression, and drug responsiveness.

The speakers will discuss how nontargeted small-molecule biomarker discovery via “discovery mass spectrometry” can enable deep human phenotyping and support large-scale epidemiological studies across broad populations, providing robust discovery for new drug targets, drug development, and precision-guided therapeutics.

You will learn:

• How emerging mass spectrometry can complement traditional genomics-based discovery
• How discovery mass spectrometry enables more rapid and comprehensive mapping of small-molecule biomarkers at population scale
• Applications for small-molecule biomarkers as part of the drug discovery and development pipeline